Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 25;10(12):e748. doi: 10.1002/iid3.748

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd.

This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

(A) SARS‐CoV‐2 wild virus neutralization test of mouse sera immunized with recombinant P1 + P2 + N vaccine formulations with either Alhydrogel (K2) or Alhydrogel + MPLA (K3) as an adjuvant. Neutralization capacity (NT100) was expressed as being able to completely inhibit virus‐induced CPEs in 100% of the wells. (B) Neutralization of P1 (containing RBD) protein–ACE2 interaction. ACE‐2, angiotensin‐converting enzyme 2; CPE, cytopathic effect; MPLA, monophosphoryl lipid A; RBD, receptor‐binding domain; SARS‐CoV‐2, severe acute respiratory syndrome coronavirus 2.